AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Advanced Topics in Hidradenitis Suppurativa

Description

The presentation focused on advanced topics in Hidradenitis Suppurativa (HS), highlighting recent research updates and management strategies. HS is more common than previously thought, with a prevalence nearing 1% and a typical patient profile of young women with long diagnostic delays. The disease significantly impacts quality of life, with high rates of depression, anxiety, and hospital readmissions comparable to chronic conditions like heart failure. The discussion emphasized the importance of connecting patients with dermatology care and utilizing evidence-based interventions. Various management approaches were covered, including pain management strategies using non-opioid medications and addressing lifestyle factors such as diet and smoking. The need for awareness of associated comorbidities, particularly cardiovascular risks, was stressed. Biologics like adalimumab and infliximab were identified as effective treatments for moderate to severe HS, although dosing needs to be adjusted according to patient responses. New biologics like secukinumab are emerging as options, and continued research is needed to personalize treatment further. The presentation concluded with a call for a combination of medical and surgical approaches in managing HS and the importance of collaborative care between dermatologists and surgical teams.

View more

Conclusions

  • Hidradenitis Suppurativa (HS) has a significant prevalence and typically affects young women with a long delay in diagnosis that leads to increased morbidity.
  • The disease is associated with high rates of hospital readmission and frequent emergency department visits, indicating a gap in effective ongoing care.
  • Patients with HS report severe pain and have higher rates of opioid prescriptions and use disorders, highlighting the need for effective pain management strategies.
  • Lifestyle modifications, including dietary changes and addressing smoking behavior, may be beneficial for managing HS.
  • HS is linked with numerous comorbidities, particularly metabolic and cardiovascular conditions, underscoring the importance of comprehensive screening.
  • Adalimumab and infliximab are considered the most effective treatments for moderate to severe HS, but treatment success requires high doses and proper management.
  • Emerging biologics, including secukinumab and bimekizumab, show promise, but further research is needed to optimize their use and identify responsive patient populations.
  • A personalized combination treatment approach is essential for managing HS effectively, reflecting the complexity of the disease.
  • Interventions to enhance patient access to dermatology care and new treatment options are critical for optimizing outcomes in HS patients.
  • JAMA Dermatol. 2017;153(8):760.
  • J Invest Dermatol. 2013;133(1):97-103.
  • J Invest Dermatol. 2013;133(6):1506-1511.
  • J Am Acad Dermatol. 1996;35(2 Pt 1):191-194.
  • J Am Acad Dermatol. 2020 Feb;82(2):366-376.
  • J Am Acad Dermatol. 2022 Jul;87(1):188-192.
  • JAMA Dermatol. 2022 Dec 1;158(12):1378-1386.
  • Br J Dermatol. 2019;180(4):774-781.
  • J Am Acad Dermatol. 2012;67(3):422-428.
  • J Am Acad Dermatol. 2007;56(4):621-623.
  • JAMA Dermatol. 2021 Feb 1;157(2):227-230.
  • J Eur Acad Dermatol Venereol. 2020 Jun 12. doi: 10.1111/jdv.16726.
  • JAMA Dermatol. 2019;155(11):1284-1290.
  • J Am Acad Dermatol. 2020;82(5):1239-1241.
  • JAMA Dermatol. 2021 Jan 1;157(1):115-117.
  • J Cutan Med Surg. 2007; 11: 125-131.
  • Australas J Dermatol. 2015; 56: 192-196.
  • J Eur Acad Dermatol Venereol. 2013; 27: 1101-1108.
  • N Engl J Med 2016; 375: 422-34.
  • Br J Dermatol. 2019 Nov;181(5):967-975.
  • Lancet. 2023 Mar 4;401(10378):747-761.
  • JAMA Dermatol. 2021 Nov 1;157(11):1279-1288.
  • Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920.
  • J Dermatolog Treat. 2012;23:28449.
  • J Clin Med. 2022 Feb 15;11(4):1007.
  • Life (Basel). 2022 Sep 29;12(10):1518.
  • Biomedicines. 2022 Oct 9;10(10):2522.
  • Dermatol Ther. 2022 Nov;35(11):e15803.
  • J Am Acad Dermatol. 2020 Feb;82(2):507-510.
  • J Am Acad Dermatol. 2019 Jul;81(1):91-101.
  • J Am Acad Dermatol. 2010;63(3):475-480.
  • JAMA Surg. 2021 Nov 1;156(11):1001-1009.